Global Nucleic Acid Therapeutics CDMO Market Size Study, by Type (Gene Therapy, RNA-based Therapies), Service (Process Development and Optimization), End-use, Application, and Regional Forecasts 2022-2032

Global Nucleic Acid Therapeutics CDMO Market Size Study, by Type (Gene Therapy, RNA-based Therapies), Service (Process Development and Optimization), End-use, Application, and Regional Forecasts 2022-2032

The Global Nucleic Acid Therapeutics CDMO Market, valued at approximately USD 13.44 million in 2023, is expected to exhibit a robust growth trajectory, achieving a CAGR of 14.20% over the forecast period 2024-2032. This burgeoning market underscores the transformative role of Contract Development and Manufacturing Organizations (CDMOs) in revolutionizing the production and optimization of nucleic acid therapeutics. As the biotechnology sector embraces innovative gene and RNA-based therapies, the demand for specialized CDMO services is accelerating, reflecting the industry's shift towards precision medicine.

Advancements in nucleic acid-based therapeutics have unlocked groundbreaking possibilities for tackling genetic disorders, cancer, and rare diseases. The CDMO market is particularly buoyed by the rising demand for efficient process development and optimization services, which are pivotal in ensuring the scalability and regulatory compliance of these therapies. Significant investments in research and development have enabled the production of high-quality therapeutic solutions, thereby catalyzing market expansion. However, the high cost of development and manufacturing remains a notable challenge, though increasing automation and technological innovations are steadily mitigating these concerns.

Regionally, North America dominates the market landscape, owing to its established biotechnology ecosystem, strong funding pipelines, and a regulatory framework conducive to innovation. Europe closely follows, driven by a robust focus on advanced therapeutics and a growing number of CDMO partnerships. Meanwhile, the Asia Pacific region is emerging as a hotbed for growth, fueled by substantial investments in biotechnology, cost-effective manufacturing capabilities, and government initiatives promoting biopharmaceutical advancements. Latin America and the Middle East & Africa are poised to witness steady growth, propelled by improving healthcare infrastructure and expanding access to advanced therapeutics.

Major market players included in this report are:
• Lonza Group AG
• Catalent, Inc.
• Thermo Fisher Scientific Inc.
• Wuxi AppTec
• Samsung Biologics
• Charles River Laboratories
• AGC Biologics
• Jubilant Biosys
• Cobra Biologics
• Cytovance Biologics
• Curia Global, Inc.
• Sarepta Therapeutics
• Takara Bio Inc.
• Genezen
• BioNTech SE

The detailed segments and sub-segments of the market are explained below:

By Type:
• Gene Therapy
• RNA-based Therapies

By Service:
• Process Development and Optimization

By Application:
• Rare Diseases
• Oncology
• Genetic Disorders
• Others

By End-Use:
• Biotechnology Companies
• Pharmaceutical Companies
• Academic and Research Institutes

By Region:

North America:
• U.S.
• Canada

Europe:
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific:
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America:
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa:
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market estimates and forecasts spanning 2022-2032.
• Detailed segmentation analysis including type, service, application, and end-use.
• Comprehensive regional insights with granular country-level data.
• Profiles of leading players in the nucleic acid therapeutics CDMO space.
• Analysis of market trends, opportunities, and challenges shaping the competitive landscape.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.